title: Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection.
abstract: We evaluated whether acyclovir suppression during human immunodeficiency virus type 1 (HIV-1) acquisition reduces HIV-1 set point, increases CD4 cell counts, and selects reverse-transcriptase mutations among 76 HIV-1 seroconverters identified in a placebo-controlled trial of twice-daily acyclovir (400 mg) for the prevention of HIV acquisition in herpes simplex virus type 2 (HSV-2)-seropositive persons (HIV Prevention Trials Network study 039). We found no significant difference in plasma HIV-1 RNA levels (P =.30) or CD4 cell counts (P =.85) between the acyclovir and placebo recipients. V75I and other mutations in HIV-1 reverse transcriptase reported from in vitro acyclovir studies were not observed. In conclusion, acyclovir suppression during HIV-1 seroconversion and the subsequent 6 months does not affect HIV-1 set point.
authors.affiliation: Department of Medicine, Schools of Medicine and Public Health, University of Washington, 325 Ninth Avenue, Seattle, WA 98104, USA. hyangkim@uw.edu
authors.forename: H Nina
authors.initials: HN
authors.lastname: Kim
authors.forename: Jing
authors.initials: J
authors.lastname: Wang
authors.forename: James
authors.initials: J
authors.lastname: Hughes
authors.forename: Robert
authors.initials: R
authors.lastname: Coombs
authors.forename: Jorge
authors.initials: J
authors.lastname: Sanchez
authors.forename: Stewart
authors.initials: S
authors.lastname: Reid
authors.forename: Sinead
authors.initials: S
authors.lastname: Delany-Moretlwe
authors.forename: Frances
authors.initials: F
authors.lastname: Cowan
authors.forename: Jonathan
authors.initials: J
authors.lastname: Fuchs
authors.forename: Susan H
authors.initials: SH
authors.lastname: Eshleman
authors.forename: Leila
authors.initials: L
authors.lastname: Khaki
authors.forename: Moira A
authors.initials: MA
authors.lastname: McMahon
authors.forename: Robert F
authors.initials: RF
authors.lastname: Siliciano
authors.forename: Anna
authors.initials: A
authors.lastname: Wald
authors.forename: Connie
authors.initials: C
authors.lastname: Celum
mesh_terms: D000212:Acyclovir / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D000998:Antiviral Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D054303:HIV Reverse Transcriptase / Q000235:genetics; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006558:Herpes Genitalis / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology; D018258:Herpesvirus 2, Human / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D008297:Male; D012367:RNA, Viral / Q000097:blood; D016896:Treatment Outcome; D019562:Viral Load; D055815:Young Adult
chemical_list: D000914:Antibodies, Viral; D000998:Antiviral Agents; D012367:RNA, Viral; C514824:reverse transcriptase, Human immunodeficiency virus 1; D054303:HIV Reverse Transcriptase; D000212:Acyclovir